---
title: 'Busulfan and subsequent malignancy: An evidence-based risk assessment'
date: '2023-10-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37856098/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231019180738&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSION: The incidence of busulfan-related secondary malignancies
  is low, and likely to be substantially less than 1% in pediatric transplant recipients,
  especially those receiving busulfan monotherapy for nonmalignant conditions other
  than ...'
disable_comments: true
---
CONCLUSION: The incidence of busulfan-related secondary malignancies is low, and likely to be substantially less than 1% in pediatric transplant recipients, especially those receiving busulfan monotherapy for nonmalignant conditions other than ...